FDA provides guidance and post hoc trial data is not considered approvable by them. That provides pretty strong evidence of how they will respond to NWBO's post hoc protocol, endpoints, external comparator and SAP when it is included in a application for commercial approval.
Market Data 
Markets 
AI
